The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward

Hello and welcome back to another edition of Endpoints Weekly! We had a huge week of stories, including all the highlights from our reporters in Berlin for the annual ESMO conference. That includes our usual Weekly writer Nicole DeFeudis, who took some well-deserved time off after the meeting, so Andrew Dunn helped out in her place. Let’s take a look at the headlines! With drugmakers facing pressure from the Trump administration, we wanted to look at how they’re seeking to get into the White Hou

Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the nipocalimab-treated group compared to placebo-treated patients Nipocalimab is the only investigational treatment

EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First FDA emergency use authorization (EUA) ever granted for NWS in dogs Action reinforces agency's commitment to providing treatment options for NWS in advance of the fly being detected in the U.S. Published literature showed Credelio may be effective in treating NWS in dogsi Preventing open wounds through effective flea and tick control is critical

The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released Oct. 23 by the Institute for Clinical and Economic Review. The analysis also found a 24% increase in the inflation-adjusted median list price during that period. Most drugs included in the analysis are almost exclusively provided by hospitals or hospital-based clinics, with the most expensive being gene or cell therapies, oncology drugs,

New Six-Mechanism Framework Decodes The Symptoms Stopping Patients From Recovering; International Handbook Series Released Long COVID isn't one disease. It's six biological disruptions creating a cascade of symptoms that compound each other.” — Dr Robert Groysman PLANO, TX, UNITED STATES, October 24, 2025 / EINPresswire.com / -- A Plano-based physician is treating multiple long COVID symptoms in unison and reporting dramatic improvements by addressing six biological mechanisms. According to a r

WASHINGTON, DC, UNITED STATES, October 24, 2025 / EINPresswire.com / -- As the demand for GLP-1 medications skyrockets, patients are increasingly targeted with compounded knockoffs that are not FDA approved and do not meet federal safety or quality standards. Many are mass-produced using unverified foreign ingredients and marketed deceptively as “personalized” care. Research shows patients using these products are twice as likely to be hospitalized compared with those on FDA-approved treatments—

Laplace announces two major achievements: successful completion of patient enrollment in its US Early Feasibility Study (EFS)on its Trans-jugular (TJ) system and successful treatment of first two patients with their Trans-femoral (TF) delivery system. PLYMOUTH, Minn., Oct. 24, 2025 /PRNewswire/ -- Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valvereplacement (TTVR) system, announced today that it has successfully completed enrollment in it

Dr Lucy Mackillop FRCP, consultant obstetric physician, reflects on the inequalities experienced during pregnancy in medical research, mortality and healthcare. Pregnancy is a time of profound physiological change, yet women and people who are pregnant or breastfeeding remain one of the most underrepresented groups in medical research. This exclusion has led to gaps in evidence, fragmented health policies and inequitable outcomes, especially for those from marginalised communities. Despite the w

ISLAMABAD, Oct. 23, 2025 /PRNewswire/ -- MindHYVE.ai™, a global leader in agentic artificial intelligence and adaptive learning technologies, has announced a landmark partnership with the Prime Institute of Health Sciences (PIHS) in Islamabad, marking a defining milestone in Pakistan's AI transformation journey. This collaboration introduces a dual-sector AI deployment—bringing ArthurAI™ to the classrooms and ChironAI™ to the hospitals of PIHS—making it the first institution in Pakistan to integ